Exploring the Synergy of G9a and ATM/ATR Pathway Interactions as a Precision Treatment Strategy in ATM-deficient Pancreatic Ductal Adenocarcinoma

Madeline M. Dzikowski,Gareth Pollin,Thiago Milech de Assuncao,Veda Gunia,Elise Leverence,Angela Mathison,Gwen Lomberk

DOI: https://doi.org/10.1124/jpet.457.972460

2024-05-15

Journal of Pharmacology and Experimental Therapeutics

Abstract:ID 97246 Poster Board 457 Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal cancer with an urgent need for more effective therapeutic strategies. Genomic analyses suggest that upwards of 25% of PDAC patients have mutations in DNA damage response (DDR) pathway genes, including ATM, BRCA1/2, and PALB2. Mutation in ataxia telangiectasia mutated (ATM) kinase, a major kinase involved in recognizing double-strand breaks, occurs in upwards of 6% of PDAC patients. If ATM is mutated, then the cells must rely on the related ATR pathway for sensing DNA damage. G9a, a lysine methyltransferase, has been localized to DNA breaks via its ATM-mediated phosphorylation at S569 or binding to RPA, an ATR target. G9a is upregulated in pancreatic cancer and its inhibition abrogates cell growth, suggesting G9a as a potential therapeutic target. Previously, our lab has performed experiments demonstrating that combined targeting of G9a and a downstream effector of ATR, CHK1, synergistically inhibit PDAC growth. However, the functional interaction between G9a and the ATM or ATR proteins remains unclear. Using linear motif analysis, we identified two potential phosphorylation sites, namely S525 and S579, in addition to the previously described S569, that may be involved in ATM/ATR signaling. Indeed, in vitro kinase assays demonstrated ATM- and ATR-mediated phosphorylation of G9a at these 3 sites. We also found increased G9a automethylation in the presence of ATM or ATR, suggesting that phosphorylation stimulates the catalytic activity of this methyltransferase. Furthermore, affinity purification of G9a followed by mass spectrometry showed interaction with ATM, ATR and ATRIP in cells. To better understand the role of G9a in both ATM and ATR signaling, we evaluated the impact of G9a knockout on DDR effector signals upon induction of DNA damage through single-stranded (ATR) or double-stranded (ATM) breaks. To determine therapeutic relevance of targeting this pathway in PDAC, we found that inactivation of both G9a and ATM reduces PDAC cell proliferation rates and colony formation more than disruption of the individual pathways. Thus, collectively, our results suggest that dual G9a-ATM inhibition may serve as a novel therapeutic strategy for PDAC and that leveraging G9a inhibition in ATM-deficient PDAC holds potential as a precision medicine approach in this patient.

pharmacology & pharmacy